New guidelines from SAMHSA released in July 2020 are designed to improve coordination of care for patients in treatment for substance disorder, while protecting confidentiality against unauthorized disclosure and use of patient information. View this HITEQ webinar on changes to SAMHSA’s 42 CFR Part 2 rule (Part 2) which protects individuals receiving substance use disorder treatment by defining privacy and security requirements for written, electronic and verbal information. This webinar features expert presenters from the University of New Hampshire Institute for Health Policy and Practice and the Center of Excellence for Protected Health Information who present on the new final Part 2 rule and future changes in the CARES Act, including what has changed, what has not changed, what this means for health centers in regard to consents and disclosures, and the implications for care coordination. This presentation also addresses privacy considerations for tele-behavioral health and exceptions during the state of emergency waiver.

Designed to engage providers seeking knowledge and skills to implement the delivery of PrEP via telehealth (known as "telePrEP") in their practices, the session showcased models of practice and the role of clinicians and navigators within a PrEP care team. Speaker presentations were followed by a facilitated question and answer session.

In this live, 60-minute webinar, expert faculty will demonstrate the use of HIV-ASSIST when making evidence-based ART decisions and will apply the tool to case discussions focused on applicability in primary care settings. 

The goal of this activity is to provide practical tools to improve the competence of primary care providers and other nonspecialists as well as global specialist healthcare professionals in making evidence-based ART decisions by increasing awareness and use of HIV-ASSIST. 

After this webinar, the participant should be better able to: 

• Confidently make use of the HIV-ASSIST tool based on a solid understanding of its functionality and the data that validate its effectiveness in HIV decision support. 
• Integrate HIV-ASSIST into the clinical workflow when selecting antiretroviral regimens for previously untreated patient cases; and 
• Select evidence-based new ART regimens for patients with stable virologic suppression and those with virologic failure through appropriate use of HIV-ASSIST.